<unk>  blocks the action of growth hormone on the growth hormone receptor to reduce the production of IGF-1. IGF-1 is responsible for most of the symptoms of acromegaly, and the normalization of its levels can control the symptoms. Long-term treatment studies with<unk>  as a monotherapy have shown it to be safe, and to date it is the most effective treatment of acromegaly as both a monotherapy and in combination with somatostatin analogues.
Pegvisomant
Lorcaserin
Tegaserod
Lisocabtagene maraleucel
Dimethyllysergamide
Naloxegol
Methomyl
Nizatidine